The psychotic complications of subcutaneous foslevodopa/foscarbidopa infusions – retrospective observational real-world data study including 198 patients

IF 8.5 1区医学 Q1 NEUROSCIENCES

NPJ Parkinson's Disease Pub Date : 2026-08-22 DOI:10.1038/s41531-026-01546-x

Joanna S. Siuda, Jakub Malkiewicz, Mateusz Toś, Agata Dymek, Monika Figura, Łukasz Milanowski, Stanisław Szlufik, Dariusz Koziorowski, Agata Gajos, Ewa Pruska, Andrzej S. Bogucki, Paulina Konieczna, Andrzej W. Bereza, Sławomir Budrewicz, Aleksandra Bręk, Agnieszka Gajda, Radosław Piekarski, Jarosław Sławek

{"title":"The psychotic complications of subcutaneous foslevodopa/foscarbidopa infusions – retrospective observational real-world data study including 198 patients","authors":"Joanna S. Siuda, Jakub Malkiewicz, Mateusz Toś, Agata Dymek, Monika Figura, Łukasz Milanowski, Stanisław Szlufik, Dariusz Koziorowski, Agata Gajos, Ewa Pruska, Andrzej S. Bogucki, Paulina Konieczna, Andrzej W. Bereza, Sławomir Budrewicz, Aleksandra Bręk, Agnieszka Gajda, Radosław Piekarski, Jarosław Sławek","doi":"10.1038/s41531-026-01546-x","DOIUrl":null,"url":null,"abstract":"Continuous foslevodopa/foscarbidopa subcutaneous infusion (LDp/CDp) is a new therapeutic option for advanced Parkinson’s disease (PD). The treatment is effective, but might be associated with psychotic symptoms (PS). The aim of the study was to assess the prevalence and factors associated with PS during LDp/CDp therapy, defined as delusions and formed hallucinations with or without preserved insight. A retrospective chart review was performed in 6 tertiary movement disorders centers in Poland, and 198 patients were included. Demographic data, PD course, MDS-UPDRS p.III OFF, and treatment before and after LDp/CDp initiation were recorded. Fifty-seven (28.8%) patients developed PS, leading to LDp/CDp treatment discontinuation in 16 (8.1%) patients. A univariate analysis was performed, and factors with p < 0.15 were included in the logistic regression model. Regression analysis revealed that the only statistically significant factor associated with PS after LDp/CDp initiation was the presence of PS at any time during the PD course (OR 6.89; 95%CI 2.76–17.15; p < 0.001). Psychotic symptoms associated with LDp/CDp treatment in the real-world setting are more common than in randomized controlled trials, and related to the presence of PS at any time before LDp/CDp initiation. Patients with a previous history of PS should be selected with caution and monitored after treatment initiation.","PeriodicalId":19706,"journal":{"name":"NPJ Parkinson's Disease","volume":"7 1","pages":""},"PeriodicalIF":8.5000,"publicationDate":"2026-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"NPJ Parkinson's Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41531-026-01546-x","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Continuous foslevodopa/foscarbidopa subcutaneous infusion (LDp/CDp) is a new therapeutic option for advanced Parkinson’s disease (PD). The treatment is effective, but might be associated with psychotic symptoms (PS). The aim of the study was to assess the prevalence and factors associated with PS during LDp/CDp therapy, defined as delusions and formed hallucinations with or without preserved insight. A retrospective chart review was performed in 6 tertiary movement disorders centers in Poland, and 198 patients were included. Demographic data, PD course, MDS-UPDRS p.III OFF, and treatment before and after LDp/CDp initiation were recorded. Fifty-seven (28.8%) patients developed PS, leading to LDp/CDp treatment discontinuation in 16 (8.1%) patients. A univariate analysis was performed, and factors with p < 0.15 were included in the logistic regression model. Regression analysis revealed that the only statistically significant factor associated with PS after LDp/CDp initiation was the presence of PS at any time during the PD course (OR 6.89; 95%CI 2.76–17.15; p < 0.001). Psychotic symptoms associated with LDp/CDp treatment in the real-world setting are more common than in randomized controlled trials, and related to the presence of PS at any time before LDp/CDp initiation. Patients with a previous history of PS should be selected with caution and monitored after treatment initiation.

查看原文本刊更多论文

foslevodopa/foscarbidopa皮下输注的精神病性并发症——包括198例患者的回顾性观察性现实数据研究

持续foslevodopa/foscarbidopa皮下输注（LDp/CDp）是晚期帕金森病（PD）的一种新的治疗选择。治疗是有效的，但可能与精神病症状（PS）有关。本研究的目的是评估LDp/CDp治疗期间PS的患病率和相关因素，定义为妄想和形成的幻觉，有或没有保留的洞察力。对波兰6个三级运动障碍中心的198例患者进行回顾性图表回顾。记录人口统计学数据、PD病程、MDS-UPDRS p.III OFF以及LDp/CDp启动前后的治疗情况。57例（28.8%）患者发生PS，导致16例（8.1%）患者停止LDp/CDp治疗。采用单因素分析，p < 0.15纳入logistic回归模型。回归分析显示，与LDp/CDp起始后PS相关的唯一具有统计学意义的因素是PD病程中任何时间是否存在PS （OR 6.89; 95%CI 2.76-17.15; p < 0.001）。在现实环境中，与LDp/CDp治疗相关的精神病症状比随机对照试验更常见，并且与LDp/CDp开始前任何时间存在PS有关。有既往PS病史的患者应谨慎选择，并在治疗开始后进行监测。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

NPJ Parkinson's Disease Medicine-Neurology (clinical)

CiteScore

9.80

自引率

5.70%

发文量

156

审稿时长

11 weeks

期刊介绍： npj Parkinson's Disease is a comprehensive open access journal that covers a wide range of research areas related to Parkinson's disease. It publishes original studies in basic science, translational research, and clinical investigations. The journal is dedicated to advancing our understanding of Parkinson's disease by exploring various aspects such as anatomy, etiology, genetics, cellular and molecular physiology, neurophysiology, epidemiology, and therapeutic development. By providing free and immediate access to the scientific and Parkinson's disease community, npj Parkinson's Disease promotes collaboration and knowledge sharing among researchers and healthcare professionals.